Lateral Pharma Pty. Ltd. has discovered peptides targeting LanC-like (LANCL) proteins reported to be useful for the treatment of diabetes, infections, inflammation, obesity, pain, metabolic, muscle and neurological disorders, among others.
Shanghai Allist Pharmaceuticals Co. Ltd. has discovered pyridopyrimidines acting as GTPase KRAS mutant inhibitors reported to be useful for the treatment of cancer.
Medshine Discovery Inc. has divulged amide compounds acting as epidermal growth factor receptor (EGFR) mutant inhibitors reported to be useful for the treatment of cancer.
Alephoson Biopharmaceuticals Ltd. has disclosed peptide-drug conjugates comprising a cell-penetrating peptide covalently linked to melphalan that are reported to be useful for the treatment of retinoblastoma.
Tonix Pharmaceuticals Holding Corp. has exercised an option to obtain an exclusive license from Columbia University for the development of a portfolio of fully human (TNX-3600) and murine (TNX-4100) monoclonal antibodies for the treatment or prophylaxis of SARS-CoV-2 infection.
Nurexone Biologic Inc. is developing Exopten as a minimally invasive Exotherapy for spinal cord injuries (SCI). The company's platform produces and loads exosomes with pharmaceutical cargo, targeting SCI intranasally in the case of lead product Exopten.
Cerevance Inc. has expanded its series B financing with an additional close of US$51 million, bringing the total series B financing to US$116 million. The proceeds will be used to advance Cerevance's therapeutics for central nervous system (CNS) diseases developed using its proprietary Nuclear Enriched Transcript Sort sequencing (Netsseq) platform.
Researchers from Institut d'Investigacions Biomèdiques August Pi i Sunyer and affiliated organizations have reported the development of novel dual CD19/BCMA CAR T cells, referred to as ARI-0003, developed through co-transduction of two lentiviral vectors encoding CARs targeting CD19 (ARI-0001) and BCMA (ARI-0002h).
RSS
